472 related articles for article (PubMed ID: 27636235)
1. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
3. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.
Douglas RG; Sharma RK; Masuyer G; Lubbe L; Zamora I; Acharya KR; Chibale K; Sturrock ED
Clin Sci (Lond); 2014 Feb; 126(4):305-13. PubMed ID: 24015848
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
Cotton J; Hayashi MA; Cuniasse P; Vazeux G; Ianzer D; De Camargo AC; Dive V
Biochemistry; 2002 May; 41(19):6065-71. PubMed ID: 11994001
[TBL] [Abstract][Full Text] [Related]
5. ACE-domain selectivity extends beyond direct interacting residues at the active site.
Cozier GE; Lubbe L; Sturrock ED; Acharya KR
Biochem J; 2020 Apr; 477(7):1241-1259. PubMed ID: 32195541
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb).
Sturrock ED; Lubbe L; Cozier GE; Schwager SLU; Arowolo AT; Arendse LB; Belcher E; Acharya KR
Biochem J; 2019 May; 476(10):1553-1570. PubMed ID: 31072910
[TBL] [Abstract][Full Text] [Related]
7. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
8. The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.
Anthony CS; Corradi HR; Schwager SL; Redelinghuys P; Georgiadis D; Dive V; Acharya KR; Sturrock ED
J Biol Chem; 2010 Nov; 285(46):35685-93. PubMed ID: 20826823
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.
Masuyer G; Akif M; Czarny B; Beau F; Schwager SL; Sturrock ED; Isaac RE; Dive V; Acharya KR
FEBS J; 2014 Feb; 281(3):943-56. PubMed ID: 24289879
[TBL] [Abstract][Full Text] [Related]
10. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
11. Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme.
Kröger WL; Douglas RG; O'Neill HG; Dive V; Sturrock ED
Biochemistry; 2009 Sep; 48(35):8405-12. PubMed ID: 19658433
[TBL] [Abstract][Full Text] [Related]
12. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
13. The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme.
Fienberg S; Cozier GE; Acharya KR; Chibale K; Sturrock ED
J Med Chem; 2018 Jan; 61(1):344-359. PubMed ID: 29206036
[TBL] [Abstract][Full Text] [Related]
14. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.
Dive V; Cotton J; Yiotakis A; Michaud A; Vassiliou S; Jiracek J; Vazeux G; Chauvet MT; Cuniasse P; Corvol P
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4330-5. PubMed ID: 10200262
[TBL] [Abstract][Full Text] [Related]
15. New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.
Sharma RK; Douglas RG; Louw S; Chibale K; Sturrock ED
Biol Chem; 2012 May; 393(6):485-93. PubMed ID: 22628311
[TBL] [Abstract][Full Text] [Related]
16. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
Douglas RG; Ehlers MR; Sturrock ED
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.
Masuyer G; Douglas RG; Sturrock ED; Acharya KR
Sci Rep; 2015 Sep; 5():13742. PubMed ID: 26403559
[TBL] [Abstract][Full Text] [Related]
19. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.
Sharma RK; Espinoza-Moraga M; Poblete H; Douglas RG; Sturrock ED; Caballero J; Chibale K
J Chem Inf Model; 2016 Dec; 56(12):2486-2494. PubMed ID: 27959521
[TBL] [Abstract][Full Text] [Related]
20. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors.
Wei L; Clauser E; Alhenc-Gelas F; Corvol P
J Biol Chem; 1992 Jul; 267(19):13398-405. PubMed ID: 1320019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
